Gulliermo Umpierrez, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1174626063
Payments from drug & device makers
Across 618 payments — averaging $10,753 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$2M
- Novo Nordisk$1.2M
- Sanofi-aventis U.S. LLC$969K
- Bayer$871K
- AstraZeneca$708K
- Merck$233K
- plus $703K from 11 others
Across 11 payments — averaging $675.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$7K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 82 | $1,988,550 |
| Novo Nordisk | 27 | $1,172,054 |
| Sanofi-aventis U.S. LLC | 21 | $969,047 |
| Bayer | 277 | $870,933 |
| AstraZeneca(2 entities) | 5 | $708,217 |
| Merck | 3 | $233,459 |
| Eli Lilly | 6 | $192,006 |
| Sanofi US Services Inc. | 29 | $181,872 |
| Boehringer Ingelheim | 29 | $153,497 |
| Lexicon Pharmaceuticals, Inc. | 20 | $78,637 |
| Abbott | 25 | $32,807 |
| Kowa Research Institute, Inc. | 13 | $16,110 |
| Boehringer Ingelheim International GmbH | 70 | $14,518 |
| Sanofi Pasteur Inc. | 1 | $14,214 |
| Xeris Pharmaceuticals, Inc. | 1 | $9,458 |
| Recordati_rare_diseases_inc. | 6 | $6,371 |
| Corcept Therapeutics | 3 | $3,437 |
How this compares
$6,645,185 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$18.3M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
- Lawrence PhillipsAtlanta$919K
- Georgia DavisAtlanta$592K
- Jonathan OwnbyAtlanta$565K
- Thaer IdreesAtlanta$505K
- Francisco PasquelAtlanta$376K
- Mary RheeAtlanta$87K
- Kate WheelerAtlanta$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.